These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 12517253)

  • 1. Cannabinoids for gastrointestinal diseases: potential therapeutic applications.
    Di Carlo G; Izzo AA
    Expert Opin Investig Drugs; 2003 Jan; 12(1):39-49. PubMed ID: 12517253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids and the digestive tract.
    Izzo AA; Coutts AA
    Handb Exp Pharmacol; 2005; (168):573-98. PubMed ID: 16596788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gastrointestinal pharmacology of cannabinoids.
    Izzo AA; Mascolo N; Capasso F
    Curr Opin Pharmacol; 2001 Dec; 1(6):597-603. PubMed ID: 11757815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoids and the gut.
    Pinto L; Capasso R; Di Carlo G; Izzo AA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):333-41. PubMed ID: 12052047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoids and the gastrointestinal tract.
    Massa F; Monory K
    J Endocrinol Invest; 2006; 29(3 Suppl):47-57. PubMed ID: 16751708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
    Darmani NA
    J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cannabis in digestive disorders.
    Goyal H; Singla U; Gupta U; May E
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.
    Pertwee RG
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1553-71. PubMed ID: 11060760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptors and their ligands.
    Pertwee RG; Ross RA
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoid overactivity and intestinal inflammation.
    Di Marzo V; Izzo AA
    Gut; 2006 Oct; 55(10):1373-6. PubMed ID: 16966693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
    Hasenoehrl C; Taschler U; Storr M; Schicho R
    Neurogastroenterol Motil; 2016 Dec; 28(12):1765-1780. PubMed ID: 27561826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoids.
    Grotenhermen F
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids and the Digestive Tract and Bladder in Health and Disease.
    Izzo AA; Muccioli GG; Ruggieri MR; Schicho R
    Handb Exp Pharmacol; 2015; 231():423-47. PubMed ID: 26408170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptors and pain.
    Pertwee RG
    Prog Neurobiol; 2001 Apr; 63(5):569-611. PubMed ID: 11164622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid pharmacology and therapy in gut disorders.
    Uranga JA; Vera G; Abalo R
    Biochem Pharmacol; 2018 Nov; 157():134-147. PubMed ID: 30076849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids and intestinal motility: welcome to CB2 receptors.
    Izzo AA
    Br J Pharmacol; 2004 Aug; 142(8):1201-2. PubMed ID: 15277313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.
    Reggio PH
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):143-60. PubMed ID: 12052032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.